ct-1 mechanistic evaluation of the effects of ranolazine on ventricular repolarization luiz...
TRANSCRIPT
![Page 1: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/1.jpg)
CT-1
Mechanistic Evaluation of the Effects of Ranolazine on
Ventricular Repolarization
Luiz Belardinelli, MD
VP, Drug Research andPharmacological Sciences
CV Therapeutics, Inc.
![Page 2: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/2.jpg)
CT-2
QT Prolongation Alone Does Not Predict Torsade de Pointes (TdP)
0
20
40
60
80
55 55 70 75Increase in QTc Interval, msec
Inci
den
ce
of
Td
P, %
A better surrogate of pro-arrhythmic potential is needed.
Canine chronic AV node block model—Vos MA, et al. Circulation. 1998;98:1125-1135.A
lmo
kala
nt
d-S
ota
lol
Do
feti
lide
Am
iod
aro
ne
![Page 3: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/3.jpg)
CT-3
Repolarizing current
Action Potential Duration (APD)
Early afterdepolarizations
↑ Dispersion of repolarization
Torsade de Pointes
SubstrateTrigger
Drug-Induced Torsade de Pointes— Relationship to EADs and Dispersion
22 Long QT
33 44
(EADs)
11IKr
Long QT
EADs ↑ DISPERSION
Torsade de Pointes
![Page 4: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/4.jpg)
CT-4
33 EADs Ectopic BeatsExtrasystoles
Initiating beats for torsade
EADs
APD ( QT)
EADsAP
Ectopic beatsEctopicbeats ECG
Inward current (eg. INa, ICa)
![Page 5: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/5.jpg)
CT-5
IKr blocker†
261
325
359
†d-Sotalol (IKr blockers) 100 µM.
LV wallLV wall
Epicardium
Mid-myocardium
Endocardium
LV chamberLV chamber
Transmural Differences of Ventricular Repolarization—A Mechanism for Arrhythmias
Normal
44
APD, msec
Arrhythmias enabled
230
271
289
98
Shimizu et al. JCE. 1999;10:154-164.
Dispersion 59
![Page 6: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/6.jpg)
CT-6
The Effects of Ranolazine On:
Ion currents
Ventricular AP (and QT)
EADs
Dispersion of ventricular repolarization
Models• Single myocytes• Cardiac tissue• Isolated hearts• Anesthetized dogs• Humans
Conditions (risk factors)• Bradycardia (pauses)• Electrolytes ( Ko, Mgo)• Gender (female)• “Ion channel mutations”• With Isoproterenol• Disease (eg, CHF, ischemia)
11
22
33
44
![Page 7: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/7.jpg)
CT-7
Ion currentEffect on
action potentialEffect on
ECGRanolazine potency IC50
IKr inhibition Lengthens QT 12 µM
Late INa inhibition Shortens QT ≥ 5 µM
Average therapeutic concentration range850 to 2500 ng/mL (~2 to 6 µM)
Late ILate INaNa effect mitigates I effect mitigates IKr Kr effecteffect
Ion Current Effects—IKr and Late INa11
![Page 8: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/8.jpg)
CT-8
Ranolazine Prolongs APD and QT Interval but This Effect Is Not Heart Rate Dependent22
↑AP
D90
, mse
c
150 100 75 600
20
40
60
80
Pacing rate, b/min
Ranolazine (5 µM)
E-4031 (1 µM)
Slope = 0.055
Slope = 0.003
†Okada et al. J Am Coll Cardiol. 1996;27:84-89. MARISA (CVT 3031).
A. Isolated hearts
E-4031 Dofetilide Ranolazine0.00
0.05
0.10
0.15
0.20
0.25
Ch
ang
e w
ith
dru
g,
slo
pe QT vs heart rate
B. Humans†
Dofetilide-like IKr blocker
![Page 9: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/9.jpg)
CT-9
EADsEctopicbeats
torsade
Ranolazine Does Not Induce Early Afterdepolarizations (EADs)33
XX XXXX†With 3 nM ATX.
1. IKr blockers (d-sotalol, E-4031) - LQT2
2. IKs blocker (chromanol 293B†) - LQT1
3. Late INa enhancer (anemone toxin, ATX-II) - LQT3
Ranolazine reverses APD (and QT) prolongation, suppresses EADs and ventricular tachycardia (VT) caused by
![Page 10: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/10.jpg)
CT-10
Ranolazine suppresses EADs induced by: quinidine, anenome toxin (ATX II), E-4031
Suppression by Ranolazine of d-Sotalol-Induced EAD in Purkinje Fiber Preparation
Control
d-Sotalol 50 µM
EAD
Ranolazine 5 µM
Ranolazine 10 µM
![Page 11: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/11.jpg)
CT-11Ranolazine Suppresses Ectopic Beats, EADs, and VT Induced by IKr Block in Female Rabbit Hearts
=
B. Ranolazine (30 µM)
Multi-channel Blocker
=
A. Control3-secpause
CT-11
![Page 12: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/12.jpg)
CT-12Ranolazine Suppresses Ectopic Beats, EADs, and VT Induced by IKr Block in Female Rabbit Hearts
C. E-4031 (60 nM)
=
IKr Blocker
D. E-4031 + Ranolazine
=
D. E-4031 + Ranolazine (5 µM)
=APDAPD APDAPD
=
A. Control3-secpause
CT-12
![Page 13: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/13.jpg)
CT-13
d-Sotalol, 100 µM ATX-II, 20 nM
Ranolazine
ATX-II
d-Sotalol
Canine LV wedge.BCL = 2000 msec.
Ranolazine Does Not Increase Transmural Dispersion of Repolarization (TDR)44
Hypokalemia
Ranolazine, µM
2 mM [K]o3 mM [K]o
0255075
100125
0 1 5 10 50 100 0 1 5 10 50 100
NS NSTDR,msec
0
25
50
75
100
125
0 1 5 10 50 100
NSTDR,msec
4 mM [K]o
Ranolazine, µM
![Page 14: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/14.jpg)
CT-14EADs and Increased Dispersion of Ventricular Repolarization Predicts the Occurrence of TdP in Humans
Drug evaluated
Drug action in canine LV myocardium
TdP reported in
humans
Induces EADs
Increases TDR
Quinidine (≤ 5 µM) ++ ++ ++d-Sotalol ++ ++ ++Terfenadine ++ ++ ++Erythromycin ++ ++ ++Cisapride ++ ++ ++Sodium pentobarbital –– –– ––Ranolazine –– ––
↓IK
r → ↑
AP
D a
nd
QT
![Page 15: CT-1 Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization Luiz Belardinelli, MD VP, Drug Research and Pharmacological Sciences](https://reader036.vdocument.in/reader036/viewer/2022062517/56649efd5503460f94c10fc7/html5/thumbnails/15.jpg)
CT-15
Summary
Drugs that cause torsade de pointes– Prolong APD/QT– Induce EADs– Augment the dispersion of repolarization present in
the normal heart
Ranolazine, 1 to 100 µM, prolongs APD & QT, but– Does not induce EADs – Does not increase dispersion of ventricular
repolarization– Suppresses the arrhythmic effects of a number of QT-
prolonging drugs– Would not be expected to cause torsade de pointes